Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

SCYX

Scynexis Inc

Jul 26 • 04:00PM ET

2.11

Dollar change +0.02
Percentage change 1.20	%

Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF BSVO IWC AVSC DFAC

Scroll to Statements

Index	-	P/E	1.13	EPS (ttm)	1.86	Insider Own	3.36%	Shs Outstand	37.21M	Perf Week	-0.94%
Market Cap	79.72M	Forward P/E	24.53	EPS next Y	0.09	Insider Trans	0.00%	Shs Float	36.51M	Perf Month	4.98%
Income	101.33M	PEG	-	EPS next Q	-0.19	Inst Own	39.22%	Short Float	3.01%	Perf Quarter	43.54%
Sales	140.38M	P/S	0.57	EPS this Y	-115.54%	Inst Trans	-0.19%	Short Ratio	4.86	Perf Half Y	16.57%
Book/sh	1.96	P/B	1.08	EPS next Y	139.81%	ROA	107.48%	Short Interest	1.10M	Perf Year	-25.44%
Cash/sh	2.13	P/C	0.99	EPS next 5Y	-	ROE	458.59%	52W Range	1.35 - 3.87	Perf YTD	-5.38%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	132.30%	52W High	-45.48%	Beta	1.50
Dividend TTM	-	Quick Ratio	3.72	Sales past 5Y	487.70%	Gross Margin	88.36%	52W Low	56.30%	ATR (14)	0.15
Dividend Ex-Date	-	Current Ratio	3.72	EPS Y/Y TTM	196.12%	Oper. Margin	52.60%	RSI (14)	51.34	Volatility	7.38% 6.85%
Employees	29	Debt/Eq	0.21	Sales Y/Y TTM	2436.77%	Profit Margin	72.18%	Recom	1.00	Target Price	6.88
Option/Short	Yes / Yes	LT Debt/Eq	0.03	EPS Q/Q	101.20%	Payout	0.00%	Rel Volume	0.16	Prev Close	2.09
Sales Surprise	472.08%	EPS Surprise	105.43%	Sales Q/Q	21.50%	Earnings	May 08 AMC	Avg Volume	226.27K	Price	2.11
SMA20	2.28%	SMA50	-2.50%	SMA200	13.74%	Trades		Volume	36,019	Change	1.20%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-22-21	Initiated	Guggenheim	Buy	$25
Jan-06-21	Initiated	Cantor Fitzgerald	Overweight	$30
Jul-11-18	Upgrade	Needham	Hold → Buy	$5
Jun-27-18	Initiated	Maxim Group	Buy	$6
Oct-24-17	Initiated	Guggenheim	Buy	$6
Jul-10-17	Initiated	ROTH Capital	Buy	$8.50
May-09-17	Downgrade	Needham	Buy → Hold
Mar-03-17	Reiterated	RBC Capital Mkts	Outperform	$15 → $11
Oct-20-16	Initiated	H.C. Wainwright	Buy	$14
Oct-07-16	Upgrade	WBB Securities	Buy → Strong Buy	$8
Oct-03-16	Resumed	Brean Capital	Buy
Aug-17-16	Initiated	Guggenheim	Buy	$15
Aug-09-16	Upgrade	WBB Securities	Speculative Buy → Buy	$8
Aug-09-16	Reiterated	Needham	Buy	$16 → $10
Mar-28-16	Initiated	Brean Capital	Buy	$16
Dec-29-15	Initiated	WBB Securities	Strong Buy	$8
Dec-29-15	Initiated	WBB Securities	Speculative Buy	$8
Nov-16-15	Reiterated	RBC Capital Mkts	Outperform	$18 → $17
Jun-10-15	Initiated	Needham	Buy	$16
May-29-14	Initiated	RBC Capital Mkts	Outperform	$17

Show Previous Ratings

Jul-23-24 07:00AM	SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports (GlobeNewswire)
Jul-22-24 06:24AM	3 Stocks Under $10 With the Potential for Massive Gains (InvestorPlace)
Jul-11-24 07:00AM	3 Dirt-Cheap Drug Developers With Blockbuster Potential (InvestorPlace) +12.69%
Jul-01-24 02:18PM	7 Undervalued Biotech Stocks to Buy for Big-Time Returns (InvestorPlace)
May-31-24 11:50AM	Hidden Gems: 3 Under-$10 Stocks Poised for 500% Growth by 2025 (InvestorPlace)
06:42AM	Loading…
May-23-24 06:42AM	3 Stocks Under $10 With Mammoth Growth Prospects (InvestorPlace) -11.46%
May-08-24 11:54PM	SCYX Stock Earnings: SCYNEXIS Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
04:51PM	Scynexis: Q1 Earnings Snapshot (Associated Press Finance)
04:30PM	SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-30-24 04:05PM	SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID) (GlobeNewswire) -7.14%
Apr-16-24 11:52AM	14 Cheap Penny Stocks to Buy According to Analysts (Insider Monkey)
Apr-09-24 04:05PM	SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) (GlobeNewswire)
Mar-28-24 11:53PM	SCYX Stock Earnings: SCYNEXIS Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace)
04:01PM	SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Jan-30-24 04:05PM	SCYNEXIS to Participate in Guggenheim's 6th Annual Biotechnology Conference (GlobeNewswire) +5.37%
05:15PM	Loading…
Jan-29-24 05:15PM	SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference (GlobeNewswire)
Jan-05-24 08:30AM	SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 27, in Milan, Italy (GlobeNewswire)
Dec-27-23 09:30AM	SCYNEXIS SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly To Discuss Their Options (GlobeNewswire)
Nov-27-23 10:33AM	11 Cheapest Stocks With Biggest Upside (Insider Monkey)
Nov-15-23 01:15PM	SCYX STOCKHOLDERS: Contact Robbins LLP for Information About Your Rights Against Scynexis, Inc. (Business Wire)
Nov-13-23 05:55PM	Scynexis: Q3 Earnings Snapshot (Associated Press Finance)
05:17PM	SCYNEXIS Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-24-23 08:00AM	SCYNEXIS Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM) (GlobeNewswire)
Oct-18-23 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating Orthofix, and Scynexis and Encourages Investors to Contact the Firm (GlobeNewswire)
Oct-16-23 08:00AM	SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM) October 20-23 in Athens, Greece (GlobeNewswire) +6.12%
Oct-02-23 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating Orthofix, and Scynexis and Encourages Investors to Contact the Firm (GlobeNewswire)
Sep-27-23 08:31PM	SCYNEXIS Issues a Voluntary Nationwide Recall of BREXAFEMME® (ibrexafungerp tablets) due to potential for cross contamination with a non-antibacterial ß-lactam drug substance (GlobeNewswire) +9.33% +9.00%
07:49AM	Verve Therapeutics (VERV) Soars 13.8%: Is Further Upside Left in the Stock? (Zacks)
Sep-25-23 08:55AM	UPDATE 4-Scynexis to recall GSK-partnered antifungal on cross contamination risk (Reuters) -34.14%
Sep-20-23 04:00AM	PTC Therapeutics (PTCT) Surges 5.8%: Is This an Indication of Further Gains? (Zacks) +5.01%
01:31PM	Loading…
Sep-04-23 01:31PM	SCYNEXIS (SCYX) Skyrockets 134% Year to Date: Here's Why (Zacks)
Aug-28-23 10:17PM	Want to Get Rich? 3 Game-Changing Penny Stocks to Buy Right Now (InvestorPlace) +11.96%
08:00AM	SCYNEXIS to Participate in September Investor Conferences (GlobeNewswire)
Aug-14-23 04:59PM	Scynexis: Q2 Earnings Snapshot (AP Finance) -6.35%
04:30PM	SCYNEXIS Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-11-23 09:09AM	10 Best Fast Growing Penny Stocks to Buy Now (Insider Monkey)
Jul-20-23 09:58AM	SCYNEXIS and Hansoh Pharma Announce NMPA Acceptance of the New Drug Application for Ibrexafungerp in China (GlobeNewswire) +5.69%
Jun-26-23 02:20PM	Deadly Fungi Are Becoming More Common and Were Running Out of Ways to Treat Them (The Wall Street Journal)
07:00AM	Doctors Desperately Need Drugs to Kill Deadly Fungi. Its an Uphill Fight. (The Wall Street Journal)
Jun-21-23 07:00AM	SCYNEXIS Announces Achievement of First Development Milestone of $25 Million Under Exclusive License Agreement with GSK (GlobeNewswire)
Jun-15-23 04:10PM	SCYNEXIS to Participate in the Maxim Group Virtual Healthcare Conference (GlobeNewswire)
May-19-23 09:22AM	WBB Research Institute Webcast Highlighted the Need For a Global Response to Candida auris and Other Deadly Antimicrobial Resistant Pathogens (Newsfile)
May-12-23 08:00AM	SCYNEXIS Reports Closing of Exclusive License Agreement with GSK for BREXAFEMME® (Ibrexafungerp Tablets) (GlobeNewswire)
May-11-23 08:45AM	Scynexis (SCYX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:37AM	Scynexis: Q1 Earnings Snapshot (AP Finance)
07:00AM	SCYNEXIS Announces First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-08-23 03:38PM	SCYNEXIS, Inc.'s (NASDAQ:SCYX) largest shareholders are individual investors with 51% ownership, institutions own 48% (Simply Wall St.)
Apr-13-23 08:30AM	SCYNEXIS to Present Ibrexafungerp Data at the 33rd Annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) April 15-18 in Denmark (GlobeNewswire)
Apr-11-23 01:33PM	We Might See A Profit From SCYNEXIS, Inc. (NASDAQ:SCYX) Soon (Simply Wall St.)
Mar-31-23 12:31PM	Scynexis (SCYX) Inks Antifungal Drug Deal With GSK (Zacks)
08:30AM	SCYNEXIS Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-30-23 01:12PM	GSK Bets On Scynexis' FDA-Approved Antifungal Drug For Over $500M In Bio Bucks (Benzinga) +76.05%
09:36AM	Anti-Fungal Maker Scynexis Stock Soars on GSK Deal (Barrons.com)
07:05AM	GSK and SCYNEXIS Announce an Exclusive Agreement to Commercialise and Further Develop Brexafemme (ibrexafungerp), a Novel, First-in-Class Medicine to Treat Fungal Infection (GlobeNewswire)
Mar-22-23 09:25AM	CDC Rings Alarm About Deadly Fungus. 6 Things to Know. (Barrons.com) +28.21%
07:06AM	SCYNEXIS, Inc. (NASDAQ:SCYX) insiders are still down US$113k after purchasing last year, recent gain helped regain some losses (Simply Wall St.)
Mar-01-23 04:03PM	Analyst Sees Multiple Chances With Over 300% Upside Potential For This Fungal Infections Stock (Benzinga) +16.11%
Jan-14-23 07:43AM	SCYNEXIS (NASDAQ:SCYX) shareholders are up 14% this past week, but still in the red over the last five years (Simply Wall St.)
Dec-01-22 08:00AM	SCYNEXIS Announces FDA Approval of Second Indication for BREXAFEMME® (ibrexafungerp tablets) for Reduction in Incidence of Recurrent Vulvovaginal Candidiasis (GlobeNewswire) -10.17%
Nov-30-22 08:30AM	SCYNEXIS Announces $3 Million National Institutes of Health Grant Has Been Awarded to Case Western Reserve University Researchers to Study Second Generation Fungerp (SCY-247) to Fight Drug-Resistant Fungi (GlobeNewswire)
Nov-17-22 08:30AM	SCYNEXIS Applauds the Biomedical Advanced Research and Development Authority (BARDA) for Its New Priority Focus on Investment in Development of Antifungal Treatments to Fight Infections Caused by Drug-Resistant Fungal Threats (GlobeNewswire)
Nov-11-22 05:37AM	SCYNEXIS Third Quarter 2022 Earnings: Misses Expectations (Simply Wall St.)
Nov-09-22 08:15AM	Scynexis (SCYX) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -19.64%
07:00AM	SCYNEXIS Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-07-22 08:30AM	SCYNEXIS Announces Publication of Review Article Highlighting Ibrexafungerp as a Potential Novel Treatment for Invasive Mold Infections in the Journal of Fungi (GlobeNewswire)
Nov-03-22 08:30AM	Pooled Data from the Pivotal Phase 3 VANISH Program Published in the Journal of Womens Health Demonstrate Significant Efficacy of Ibrexafungerp Over Placebo for Treatment of Vaginal Yeast Infection (GlobeNewswire)
Nov-02-22 10:01AM	Earnings Preview: Scynexis (SCYX) Q3 Earnings Expected to Decline (Zacks)
Nov-01-22 08:30AM	SCYNEXIS to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 9 (GlobeNewswire)
Oct-25-22 08:30AM	Biopharma Veteran Ivor Macleod Joins SCYNEXIS as Chief Financial Officer (GlobeNewswire) +5.41%
Oct-24-22 08:30AM	SCYNEXIS Presents Positive Interim Data of Oral Ibrexafungerp for Severe Fungal Infections from Ongoing Phase 3 FURI Study During IDWeek 2022 (GlobeNewswire) -7.11%
Oct-20-22 07:00AM	SCYNEXIS Provides Corporate, Commercial and R&D Strategy Updates to Expand Market Potential for Its First-in-Class Antifungal (GlobeNewswire) -14.97%
Oct-11-22 08:30AM	SCYNEXIS to Present Positive Interim Data from the Phase 3 FURI Study of Oral Ibrexafungerp at IDWeek 2022 (GlobeNewswire)
Oct-07-22 09:25AM	Great news for SCYNEXIS, Inc. (NASDAQ:SCYX): Insiders acquired stock in large numbers last year (Simply Wall St.)
Sep-09-22 08:30AM	SCYNEXIS to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Sep-08-22 08:30AM	SCYNEXIS Presents Positive Interim Data of Ibrexafungerp for Refractory Candida Infections from Ongoing Phase 3 FURI Study During the Mycoses Study Group Education and Research Consortium (MSGERC) Biennial Meeting (GlobeNewswire)
Sep-01-22 08:30AM	SCYNEXIS to Present Posters Highlighting Ibrexafungerp Data at Four Upcoming Scientific Meetings in September 2022 (GlobeNewswire)
Aug-15-22 08:15AM	Scynexis (SCYX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:00AM	SCYNEXIS Reports Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-09-22 08:30AM	SCYNEXIS to Report Second Quarter 2022 Financial results and Provide a Corporate Update on August 15 (GlobeNewswire) -6.90%
Aug-04-22 08:30AM	SCYNEXIS Presents Positive Data from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections During the 2022 IDSOG Annual Meeting (GlobeNewswire) +8.70%
Aug-01-22 08:30AM	SCYNEXIS Announces U.S. Food and Drug Administration Acceptance and Priority Review of the Supplemental New Drug Application for BREXAFEMME® (ibrexafungerp tablets) for Prevention of Recurrent Vaginal Yeast Infections (GlobeNewswire)
Jul-19-22 08:30AM	SCYNEXIS Presents Positive Data from Phase 3 CANDLE Nested Sub-Study Investigating Ibrexafungerp in Women with Recurrent Yeast Infections Who Failed Fluconazole During the ISSVD XXVI World Congress and International Vulvovaginal Disease Update (GlobeNewswire)
Jul-14-22 08:30AM	SCYNEXIS to Present Data from the CANDLE Nested Sub-Study of Ibrexafungerp During the International Society for the Study of Vulvovaginal Disease (ISSVD) XXVI World Congress and International Vulvovaginal Disease Update (GlobeNewswire)
Jun-29-22 07:06AM	The past five years for SCYNEXIS (NASDAQ:SCYX) investors has not been profitable (Simply Wall St.)
Jun-23-22 08:30AM	SCYNEXIS Announces Initiation of New Phase 3b Study (VANQUISH) to Evaluate Oral Ibrexafungerp as a Treatment for Complicated Vulvovaginal Candidiasis (VVC) in Patients Who Failed to Respond to Treatment with Fluconazole (GlobeNewswire)
Jun-08-22 08:30AM	SCYNEXIS Announces Submission of Supplemental New Drug Application of BREXAFEMME® (ibrexafungerp tablets) to the U.S. Food and Drug Administration for an Expanded Indication for the Prevention of Recurrent Vaginal Yeast Infections (GlobeNewswire)
Jun-03-22 04:05PM	SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-20-22 08:30AM	SCYNEXIS to Present at Upcoming H.C. Wainwright Global Investment Conference (GlobeNewswire)
May-12-22 08:35AM	Scynexis (SCYX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:00AM	SCYNEXIS Reports First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
May-10-22 08:30AM	SCYNEXIS Presents New Interim Positive Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting (GlobeNewswire)
May-05-22 08:30AM	SCYNEXIS to Report First Quarter 2022 Financial Results and Provide a Corporate Update on May 12 (GlobeNewswire) -6.90%
May-04-22 08:30AM	SCYNEXIS to Present New Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting (GlobeNewswire)
Apr-30-22 08:55AM	The CEO, President & Director of SCYNEXIS, Inc. (NASDAQ:SCYX), Marco Taglietti, Just Bought 68% More Shares (Simply Wall St.)
Apr-27-22 08:30AM	SCYNEXIS Presents Data Analyses Showing Ibrexafungerps Potential to Fight Invasive Candidiasis and Candidemia, Including Infections Caused by Candida Auris, During the 32nd Annual European Congress of Clinical Microbiology & Infectious Diseases (GlobeNewswire)
Apr-26-22 05:18PM	SCYNEXIS Announces Closing of $45 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants (GlobeNewswire)
Apr-22-22 08:15AM	SCYNEXIS Announces Pricing of $45 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants (GlobeNewswire) -25.80%
08:00AM	SCYNEXIS Announces Positive Interim Data from Phase 3 FURI and CARES Studies Highlighting Oral Ibrexafungerp's Potency Against Severe Fungal Infections (GlobeNewswire)
Apr-21-22 04:01PM	SCYNEXIS Announces Launch of Public Offering of Common Stock and Warrants (GlobeNewswire)
Apr-20-22 08:30AM	SCYNEXIS to Present Positive Interim Data from Ongoing FURI and CARES Studies at the 32nd Annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) Being Held April 23-26 in Lisbon, Portugal (GlobeNewswire)

SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SCYX

Scynexis Inc

Upgrade your FINVIZ experience